Orforglipron Wins Fast-Track FDA Approval for Chronic Weight Management: An Expert Discussion

The US Food and Drug Administration approved orforglipron (Foundayo; Eli Lilly and Company) for chronic weight management in adults with obesity, or in adults with overweight and at least 1 weight-related comorbidity.

Unlike oral semaglutide (Wegovy), which must be taken on an empty stomach with a small volume of water and separated from other medications and food, orforglipron can be taken with food, other pills, and coffee. In the video above, Diana Isaacs, PharmD, and Natalie Bellini, DNP, emphasized that this flexibility may significantly improve adherence in real-world primary care populations.

Small-Molecule, Non-Peptide Design

Orforglipron is a small-molecule, non-peptide GLP-1 agonist, which differentiates it from traditional peptide-based GLP-1 agents that require absorption enhancers and strict administration protocols. Its structure allows for:

• Oral dosing without complex timing instructions
• Maintenance of therapeutic GLP-1 activity despite standard meals and concomitant medications

Obesity-First Approval Path and Efficacy

In a departure from prior GLP-1 drugs that were approved first for type 2 diabetes, orforglipron’s initial indication is obesity/weight management. It is being studied separately for type 2 diabetes. The approval of orforglipron was supported by the phase 3 ATTAIN clinical development program, which included 2 global, randomized, double-blind, placebo-controlled trials evaluating efficacy and safety over 72 weeks.

In the ATTAIN-1 study:

• Patients on orforglipron lost an average of 27.3 lb (12.4% of body weight)
• Placebo patients lost 2.2 lb (0.9%)

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.